Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) announced a major clinical victory on Tuesday, revealing that their investigational antibody, duvakitug (formerly TEV-574), successfully maintained disease control in patients with inflammatory bowel disease (IBD) for nearly a full year.
The results from the RELIEVE UCCD Phase 2b long-term extension study followed 130 patients who had originally responded to the drug during a 14-week induction phase.
After 44 weeks of maintenance therapy—totaling nearly 60 weeks of total exposure—the drug demonstrated what analysts are calling "unprecedented" durability for a TL1A inhibitor, a hot new class of autoimmune therapies.
The data showed a clear dose-dependent response across both primary forms of IBD.
In the Ulcerative Colitis (UC) cohort, 58% of patients on the high dose (900 mg) achieved clinical remission at week 44, compared to 47% on the lower dose.
In the Crohn’s Disease (CD) group, 55% of high-dose patients reached the primary endpoint of endoscopic response, a rigorous measure of internal healing.
Meanwhile, the drug’s safety profile remained consistent with earlier trials, with common side effects limited to mild respiratory infections and nasopharyngitis.
The timing is critical for Teva as it executes its "Pivot to Growth" strategy.
The IBD market is projected to reach over $30 billion by 2030, and duvakitug is the crown jewel of Teva’s innovative pipeline.
The positive maintenance data serves as a de-risking event for the massive Phase 3 program currently underway.
Under the terms of their 2023 collaboration, Teva and Sanofi are splitting development costs equally.
If approved, Teva will lead commercialization in Europe and Israel, while Sanofi will take the lead in North America and Japan.